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Background: Few approaches exist to rationally engineer
live, attenuated virus vaccines.
Results: Converting the conserved catalytic regulator
lysine of the viral polymerase to arginine produces a slow,
attenuated virus that elicits a protective immune
response.
Conclusion: We have developed a polymerase mecha-
nism-based strategy for viral attenuation and vaccine
development.
Significance: This strategy may be used to create live,
attenuated vaccines for other viruses.
Live, attenuated vaccines have preventedmorbidity andmor-
tality associated with myriad viral pathogens. Development of
live, attenuated vaccines has traditionally relied on empirical
methods, such as growth in nonhuman cells. These approaches
require substantial time and expense to identify vaccine candi-
dates and to determine their mechanisms of attenuation. With
these constraints, at least a decade is required for approval of a
live, attenuated vaccine for use in humans.We recently reported
the discovery of an active site lysine residue that contributes to
the catalytic efficiency of all nucleic acid polymerases (Castro,
C., Smidansky, E. D., Arnold, J. J., Maksimchuk, K. R.,Moustafa,
I., Uchida, A., Götte, M., Konigsberg, W., and Cameron, C. E.
(2009)Nat. Struct.Mol. Biol. 16, 212–218). Here we use amodel
RNA virus and its polymerase to show that mutation of this res-
idue from lysine to arginine produces an attenuated virus that is
genetically stable and elicits a protective immune response.
Given the conservation of this residue in all viral polymerases,
this study suggests that a universal, mechanism-based strategy
may exist for viral attenuation and vaccine development.
The current state of the art for vaccinology limits the devel-
opment of a vaccine as a first response to an epidemic caused by
the natural or intentional spread of a new virus. Live, attenuated
virus vaccines are most efficacious because both humoral and
cellular immunity are generally elicited. In addition, transmis-
sion of the vaccine strain can lead to herd immunity. Creation
of a live, attenuated virus vaccine usually involves random
approaches, for example adaptation of a virus to growth at low
temperatures or in nonhuman cell cultures (2). The process of
adaptation leads to numerous genetic changes, only a subset of
which may be responsible for the attenuated phenotype in
humans (3, 4). The regulatory process now requires an absolute
determination of the genetic basis for the attenuated phenotype
(5), allowing assessment of the “stability” of the attenuated phe-
notype. This regulatory requirement represents a high hurdle
for vaccine development such that if the Sabin poliovirus (PV)3
vaccines needed to meet this criterion, they would not be
approved today.
There has been a flurry of activity by many laboratories to
develop rational approaches for vaccine development (2,
6–10). One of these approaches involved increasing the repli-
cation fidelity of the RNA-dependent RNA polymerase (RdRp)
of a prototypical positive strand RNA virus, PV (10). Enhanced
replication fidelity of the viral RdRp has two major outcomes.
First, the reduced genetic variation is attenuating because vari-
ants in the population required to evade barriers of the host are
not generated at the appropriate frequency (11). Second, the
enhanced fidelity reduces the frequency of genetic reversion to
a wild-type, pathogenic phenotype (12). There is now evidence
in several systems that RdRp fidelity is a determinant of viral
pathogenesis and virulence (11–18). Unfortunately, none of the
mutations in the RdRp gene that lead to increased replication
fidelity are at positions conserved across virus families, making
it difficult to extrapolate attenuation by enhanced fidelity to
other systems.
In this study, we show thatmutating the conserved active site
lysine residue that serves as a general acid catalyst during nucle-
otide incorporation to arginine produces a viral RdRp that rep-
licates slower with higher fidelity. This virus variant is geneti-
cally stable, replicates well in cell culture, is attenuated (fails to
cause disease), and elicits a protective immune response in vivo.
Due to the conservation of this residue in viral polymerases, this
study suggests that a universal, mechanism-based strategy may
exist for viral attenuation and vaccine development.
EXPERIMENTAL PROCEDURES
Expression and Purification of PV RdRp—Construction of
pET26Ub-PV-3D expression plasmids were described previ-
ously (1, 19). PV RdRp was expressed and purified as described
previously (1, 19).
Kinetic Analysis of PV RdRp—Nucleotide incorporation
experiments were performed essentially as described previ-
ously (1, 23).
Sequence Alignments—All sequences were obtained from the
National Center for Biotechnology Information (NCBI) Data-
base. Sequences were aligned using ClustalW2 and based upon
alignments previously published (22).* This work was supported, in whole or in part, by National Institutes of Health
Grant AI053531 (to C. E. C.).
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Cells and Viruses—HeLa S3 cells were obtained from the
American Type Culture Collection (ATCC) and grown in
DMEM/F-12 medium plus 10% fetal bovine serum, 100
units/ml penicillin, and 100 units/ml streptomycin. PV type 1
Mahoney was used throughout this study.
Construction of Mutated Viral cDNA Clones and Replicons—
The expression plasmid encoding the K359R mutation (1) was
digested and inserted into an intermediate plasmid, pUC18-
BglII-EcoRI-3CD (referred to as pUC-3CD in Ref. 20), and then
the fragment between BglII andApaI was cloned into either the
subgenomic replicon, pRLucRA, or viral cDNA, pMovRA. Plas-
mids were linearized and used in RNA transcription reactions
as described previously (21).
Infectious Center Assays—Infectious center assays were per-
formed as described previously (21).
Virus Isolation, Titer, and One-step Growth Curves—Virus
was harvested and titered by plaque assay as described previ-
ously (21). For TCID50, virus was serially diluted in medium,
and each dilution was added to 10 wells of a 96-well plate pre-
viously seededwith 5 103HeLa cells. Plates were incubated at
37 °C for 7 days before being manually scored for Cytopathic
effect. The percentage of wells with CPE for each dilution was
used to calculate viral titer (in TCID50/ml). When the same
stock was titered by bothmethods, 1 pfu/ml was approximately
equivalent to 20 TCID50/ml. To analyze one-step virus growth,
cells in 12-well plates were infected with virus at a multiplicity
of infection of 10. Virus was allowed to adsorb, cells were
washed with PBS, medium was added to each well, and cells
were incubated at 37 °C for various times after infection. Virus
was harvested by three repeated freeze-thaw cycles, and virus
titers were performed by TCID50 assays.
Northern Blot Analysis—Northern blots were performed as
described previously (21).
Ribavirin Sensitivity Assay—HeLa cell monolayers in 6-well
plates were pretreated for 1 h with various concentrations of
ribavirin and then infected with 50 pfu ofWT, G64S, or K359R
PV, incubated for 20min to allow for virus adsorption, and then
washed and overlaid with 0.5% agarose medium containing the
same concentration of ribavirin. Plates were incubated for 3–4
days at 37 °C before overlays were removed, and monolayers
were stainedwith crystal violet. Plaqueswere counted and com-
pared with the untreated (0 mM ribavirin) control dish. To
determine the IC50 value, the percentage of plaques was plotted
as a function of ribavirin concentration and fit to a sigmoidal
dose response equation (Equation 1)
Y  A  100  A/1  ribavirin/IC50
H (Eq. 1)
where Y is the percentage of plaques relative to untreated cells,
A is theminimumpercentage of plaques, andH is theHill Slope.
Subgenomic Replicon Assays—Subgenomic replicon assays
were performed as described previously using a luciferase-ex-
pressing, subgenomic replicon (21).
Mouse Infection and Protection—Micewere bred and housed
in standard ventilated caging for all experiments. Viral stocks
generated in serum-free medium, harvested and titered as
above, were diluted to 2  109 TCID50 per 3 ml of serum-free
medium. Six-to-eight-week-old outbred (ICR) mice transgenic
for the PV receptor (cPVR) were infected with PV by intraperi-
toneal injection in 3 ml of serum-free medium (or mock-in-
fected with 3 ml of serum-free medium alone). Mice were
observed for 14 days for signs of disease and were euthanized
upon showing dual limb paralysis or paralysis such that their
ability to obtain food and water was compromised; this was in
accordance with approval by the Institutional Animal Care and
Use Committee (IACUC) at Penn State. Surviving mice were
challenged using the same methods with a lethal dose (2  109
TCID50) ofWT PV 1month after infection and observed for 14
days as above.
Statistical Analysis—Survival curves were performed using
the product limit method of Kaplan and Meier and survival
curve comparisons using the log rank test as provided by
GraphPad Prism 4. p values are indicated.
RESULTS AND DISCUSSION
It is long established that nucleic acid polymerases use a two-
metal-ion mechanism for nucleotidyl transfer (Fig. 1A)(24). In
this mechanism, two magnesium ions are used to organize the
reactants, 3-OH of primer and -phosphorous atom of the
nucleoside triphosphate (NTP), and onemagnesium ion lowers
the pKa of the 3-OH for deprotonation by a base that has yet to
be identified. We recently expanded the chemical mechanism
of nucleotidyl transfer to include a general acid, which proto-
nates the pyrophosphate leaving group of the NTP substrate
and contributes a 50–2000-fold rate enhancement to nucleoti-
dyl transfer (Fig. 1A)(1, 23). In the case of PV RdRp, the general
acid is Lys-359. This residue is located in a motif termed D that
is conserved in the structures of all RdRps and reverse tran-
scriptases (Fig. 1B). Importantly, an orthologous residue is pre-
dicted in RNA viruses for which vaccines could be of great ben-
efit (Fig. 1C).
The RdRp from PV is the only enzyme in this superfamily of
enzymes for which a detailed, kinetic description of the mech-
anism and fidelity exists (1, 23, 25). PV RdRp will assemble
stable elongation complexes on symmetrical RNAprimer-tem-
plates, referred to as sym/sub (Fig. 1D)(26). Nucleotide addition
can be evaluated by monitoring changes in extension of 32P
end-labeled RNA (26). The PV RdRp with Lys-359 substituted
by Arg (referred to as K359R RdRp) is known to catalyze nucle-
otidyl transfer at a rate 10-fold lower than wild type (1). How-
ever, the impact of this change on fidelity has not been studied.
A slow polymerase with high incorporation fidelity could con-
tribute to a stable, attenuated phenotype in the context of a
virus. Fidelity was evaluated by two approaches using sym/
sub-U, which has a uridine as the first templating nucleotide
(Fig. 1D). The first approach monitored utilization of GTP
(misincorporation); the second approachmonitored utilization
of ribavirin triphosphate (RTP). RTP was chosen because the
first high fidelity variant of PV RdRp, G64S, was isolated by
selection ofmutantswith reduced sensitivity to ribavirin, which
was caused by reduced utilization of RTP (12, 16). Under con-
ditions in which AMP incorporation went to completion for
both WT and K359R RdRps (lanes 2 and 5, Fig. 1E), a sub-
stantial reduction in GMP misincorporation and ribavirin
monophosphate incorporation was observed for K359R
RdRp (Fig. 1E, lanes 6 and 7) relative to WT RdRp (Fig. 1E,
lanes 3 and 4). To obtain a more quantitative perspective of
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the change in fidelity, we evaluated the kinetics of incorpo-
ration of the various nucleotides at saturating concentra-
tions. K359R RdRp was on the order of 5-fold more faithful
than WT RdRp (Fig. 1F). Under the same conditions, G64S
RdRp exhibited only a 2–3-fold enhancement in fidelity (Fig.
1F)(12). Because GMP incorporation opposite uridine rep-
resents the most facile misincorporation event, this study
only establishes a lower limit for the increase in fidelity
caused by the K359R substitution.
To determine how the biochemical changes associated with
the K359R RdRp impact virus multiplication in cell culture, we
constructed a PV genome encoding theK359RRdRp. TheAAA
codon encoding lysine was changed to the CGT codon encod-
ing arginine. Therefore, genetic reversion requires two trans-
version mutations, a very inefficient event that provides some
barrier to reversion. Transcripts encoding the K359R RdRp
were on the order of 10-fold less cytolytic to HeLa cells than
those encodingWT RdRp (Fig. 2A). K359R PV recovered from
this type of experiment exhibited a reduced rate of virus pro-
duction, with a final yield 10-fold less than that of WT PV (Fig.
2B). Despite the reduced fitness of K359R PV, both the K359R
change and the corresponding phenotype were stable over
eight serial passages at a multiplicity of infection of infection
from 0.1 to 1 (data not shown). Interestingly, the duration of
neither the eclipse phase (lag) nor the exponential phase of
infectious virus production was reduced by the magnitude
of the nucleotidyl transfer rate (10-fold) measured in vitro (Fig.
2B). It is therefore possible that RNA synthesis does not con-
tribute directly to the rate-limiting step for virus production.
To address this possibility, we used Northern blotting to eval-
uate RNA synthesis as a function of time after infection. We
found that the kinetics of RNA accumulation were clearly
FIGURE 1. PV RdRp Lys-359 is a determinant of catalytic efficiency and
fidelity. A, Lys-359 functions as a general acid catalyst. As the transition state
of nucleotidyl transfer is approached, primer 3-OH proton, Ha, is transferred
to an unidentified base (B), and pyrophosphate leaving group is protonated
(Hb) by a conserved basic amino acid in the active site, in the case of PV RdRp,
Lys-359 (1). B, structure of PV RdRp. Palm, fingers, and thumb subdomains are
indicated. Conserved structural motifs are colored: A, red; B, green; C, yellow;
D, blue; E, purple; F, orange; G, black. Lys-359 in motif D is indicated (Corey-
Pauling-Koltun, orange). C, the motif D lysine that functions as a general acid
is conserved in viral RdRps. Sequence alignments of motifs C and D from the
indicated positive- and negative-strand viral RdRps are shown. Numbers indi-
cate position from first amino acid of the RdRp domain and length separating
motifs C and D. Conserved residues are shown in boldfaced type. Residues
conserved within a virus group are underlined. D, primed template use is
referred to as sym/sub-U and contains a uracil as the first templating base.
E, reaction products from PV RdRp-catalyzed nucleotide incorporation using
indicated nucleotide and sym/sub-U. K359R PV RdRp incorporated GMP and
ribavirin monophosphate less efficiently than WT. The percentage of RNA
product relative to the correct nucleotide (ATP) is shown. F, K359R PV RdRp is
more faithful than the WT enzyme. Observed rate constants for correct and
incorrect nucleotide incorporation catalyzed by WT, K359R, and G64S PV
RdRp are shown. The relative fidelity or error frequency is shown. a, Values for
G64S PV RdRp taken from a previous study (12).
FIGURE 2. K359R PV is viable but attenuated in cell culture. A, infectious
center assay. The specific infectivity of viral RNA was 2  104 and 2  103 for
WT and K359R, respectively. und. indicates addition of undiluted sample. B
and C, kinetics of virus growth for K359R PV. Viral titer (TCID50/ml) was plotted
as a function of time after infection. Error bars indicate S.D. Duplicate infected
samples were used for RNA isolation and Northern blot analysis (C). D, kinetics
of RNA synthesis using a luciferase-expressing, subgenomic replicon. Lucifer-
ase-specific activity is reported in relative light units (RLU) per microgram of
total protein in the extract. WT  guanidine hydrochloride (GuHCl) represents
a control for translation of input RNA without replication. Shown is one rep-
resentative data set. E and F, ribavirin sensitivity. Plaque numbers were plot-
ted against ribavirin concentration normalized to untreated (0 mM) control
(F). The solid line represents the fit of the data to a sigmoidal dose response
equation (Equation 1), yielding IC50 values of 0.55  0.03, 2.05  0.10, and
1.25  0.13 mM for WT, G64S, and K359R PV, respectively.
REPORT: Polymerase Mechanism-based Strategy for Vaccines
31620 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287 • NUMBER 38 • SEPTEMBER 14, 2012
diminished (Fig. 2C). To increase the signal for replication, we
engineered the K359R substitution into a PV subgenomic rep-
licon that permits RNA synthesis to be evaluated indirectly by
monitoring luciferase activity. In this experiment, it was clear
that at least a 10-fold reduction occurred in all phases of
genome replication (Fig. 2D). Collectively, these data suggest
that the biochemical defect associated with the Arg-359 substi-
tution is manifested in cells.We interpret the reduction in viral
genomes, and consequentially reduced infectious virus, to
mean that some innate process capable of squelching RNA syn-
thesis is manifested when replication requires longer than 4 h
for completion. A PV variant exhibiting increased nucleotide
incorporation fidelity exhibits reduced sensitivity to the antivi-
ral nucleoside, ribavirin (12, 16). Therefore, to assess K359R
fidelity in cells, we evaluated the sensitivity of K359R PV to
ribavirin. By plaque assay, there was a clear reduction in sensi-
tivity of K359R PV to ribavirin when compared with WT PV
(Fig. 2E). The ribavirin resistance phenotype was on par with
that observed for G64S PV (Fig. 2E), consistent with biochem-
ical data for the corresponding polymerases (Fig. 1F). More
rigorous analysis revealed an intermediate resistance for K359R
PV relative toWT andG64S PVs (Fig. 2F). It is possible that the
reduced speed of genome replication is antagonistic with the
increased fidelity of genome replication, leading to the obser-
vation that K359R PV is less fit thanG64S PV in the presence of
ribavirin.
In cells, K359R PV is delayed in growth but replicates with
high fidelity. These characteristics predict that K359R PV
should be more attenuated in animals than G64S PV.We com-
pared the virulence of K359R PV with G64S and WT PVs in a
mouse transgenic for the PV receptor (27). In this system, infec-
tion by WT PV is generally lethal (27). At the highest dose of
K359R PV readily attainable, none of the inoculated mice
showed any symptoms of infection (Fig. 3A). At the same dose,
both G64S and WT PVs caused two-limb paralysis (IACUC-
approved end point for these experiments) (Fig. 3A). Previous
studies of G64S PV used a different end point, thus permitting
the diminished virulence of G64S PV relative to WT PV to be
observed (11). To determine whether K359R PV actually repli-
cates in the mice and has potential as a vaccine candidate, we
performed a challenge experiment with WT PV. Mice were
inoculated with K359R PV. Four weeks after inoculation, the
mice were challenged with a lethal dose of WT PV. All of
the K359R PV-inoculated mice survived this lethal challenge;
none of the mock-infected (naive) mice survived (Fig. 3B). We
conclude that K359R PV replicates in these animals as UV-
inactivated, replication-incompetent PV is incapable of elicit-
ing immunity sufficient to protect against a lethal challenge
with WT PV (10, 11). To place the protection afforded by this
mechanism-based approach into context, we compared the
efficacy of K359R PV vaccination with that of Sabin-1 PV.
Doses of K359R PV below 2  109 infectious units were less
effective than the corresponding dose of Sabin-1 PV (Fig. 3C).
Overall, the efficacy of K359R PV appeared on the order of one
log lower than Sabin-1 PV in this model (Fig. 3C). Given that
Sabin-1 PV has 57 nucleotide changes that cause 21 amino acid
changes relative to the Mahoney strain of PV (3), the attenua-
tion and stability afforded by this single change of lysine to
arginine is remarkable.
We have used the PV system to show that the general acid of
the viral RdRp can be changed to create a slower, more faithful
RdRp derivative that produces an attenuated virus capable of
protecting mice against a lethal challenge with wild-type virus.
This is the first polymerase mechanism-based approach for
viral attenuation. Importantly, this attenuation strategy can be
easily and rapidly deployed in any positive-strand RNA virus,
and perhaps other RNA and DNA viruses as well. As long as the
polymerase belongs to one of the known superfamilies, sequence
alone should be sufficient to identify the general acid (e.g. Fig. 1C).
The polymerases of negative- and double-strand RNA viruses are
all predicted to have this conserved lysine residue (22, 28). In addi-
tion, the replicative polymerases of herpes-pox and adenoviruses,
all DNA viruses, are B-family polymerases predicted to have this
conserved lysine (29).Evaluating the impactof theLys-to-Argsub-
stitution in other viruses will be necessary to determine how gen-
eralizable this attenuation strategy will be.
A great benefit associated with this attenuation mechanism
is that it should combine in a predictable manner with other
rational attenuation strategies, especially those that alter codon
pair bias (7, 8) or incorporate microRNAs (6, 9). The increased
fidelity of RNA synthesis may further diminish the rate of
genetic reversion and restoration of the virulent phenotype.
FIGURE 3. K359R PV is attenuated and protective in the cPVR mouse
model. A, mouse infections with WT, K359R, and G64S PVs. cPVR mice were
infected by intraperitoneal injection with serum-free medium containing 2 
109 TCID50 of WT, K359R, or G64S PV. K359R PV-infected mice showed no
signs of infection or disease; n 	 10 for WT and K359R PV and n 	 15 for G64S
PV. Survival curves for mice infected with K359R and G64S PV are significantly
higher than those for mice infected with WT PV (p 
 0.0001, p value of 0.002,
respectively, Kaplan-Meier test). B, mouse protection studies. Mice immu-
nized with K359R PV as above or mock-immunized with serum-free medium
alone (Naive) were infected 4 weeks after immunization with a lethal dose of
WT PV (2  109 TCID50); n 	 10. Survival curves for mice immunized with
K359R PV are significantly higher than those for mice immunized with control
serum-free medium (p 
 0.0001, Kaplan-Meier test). C, comparison of protec-
tion between K359R PV and the Sabin type 1 PV vaccine strain. The percent-
age of protection is shown. Mice immunized with either K359R or Sabin-1 PV
with the indicated dose were infected 4 weeks after immunization with a
lethal dose of WT PV (2  109 TCID50); n 	 5, errors indicate S.E. Two inde-
pendent trials were performed with K359R PV.
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An immediate application of this technology is in the pro-
duction of seed stocks for creation of inactivated PV vaccine.
Currently, wild-type strains are used, increasing production
costs due to containment and limiting the number of sites glob-
ally capable of producing the vaccine, which leads to expenses
for shipment and storage. An attenuating mutation in poly-
merase-coding sequencewill not alter the stability or antigenic-
ity of the capsid. It is also easy to envision using this polymerase
mechanism-based strategy when the toxicity associated with
virus is sufficiently high that virus yield is negatively impacted.
This circumstancemay have contributed to the shortage of vac-
cine for the swine flu outbreak in 2009.
Viruses encoding polymerases with a substitution of the gen-
eral acid may also prove to be useful reagents to study virus
molecular and cellular biology. The 10-fold reduction in polym-
erase activity appears to prolong the kinetics of virus multipli-
cation. Therefore, processes that occur early during infection
may now be slow enough to interrogate experimentally. For
example, during the first 30 min to 2 h after infection of HeLa
cells by PV, the site of replication changes from the Golgi appa-
ratus to the endoplasmic reticulum (30). Expanding the dura-
tion of time required for this transition will facilitate further
dissection of this process and identification of host factors par-
ticipating in the transition.
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